Outcomes of active surveillance for men with intermediate-risk prostate cancer. - Wikidata - wikimedia - TriplyDB

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

http://www.wikidata.org/entity/Q34679207

about

Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes Active surveillance for prostate cancer: current evidence and contemporary state of practice Can contemporary patients with biopsy Gleason score 3+4 be eligible for active surveillance?Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort Integration of multiparametric MRI into active surveillance of prostate cancer.Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.Multi-parametric magnetic resonance imaging as a management decision tool.Evolution from active surveillance to focal therapy in the management of prostate cancer.Prostate-specific antigen screening in prostate cancer: perspectives on the evidence Active surveillance in men with low-risk prostate cancer: current and future challenges.The role of MRI in prostate cancer active surveillance.miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.The impact of financial interest in intensity-modulated radiation therapy on the utilization of radiation therapy for treatment of newly diagnosed prostate cancer: a single center experience Insignificant disease among men with intermediate-risk prostate cancer Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy.Role of active surveillance in the management of localized prostate cancer.Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer.Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.Active surveillance for prostate cancer compared with immediate treatment: an economic analysis Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes.Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation Active surveillance for intermediate-risk prostate cancer Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.Active surveillance for prostate cancer: overview and update.Comparative effectiveness research in localized prostate cancer treatment.Active surveillance for clinically localized prostate cancer--a systematic review.Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer.

P2860

Q27010695-BDA510BC-41D5-48C9-8BE0-C89DC7589D50 Q28066534-61AF1959-1920-458B-AC7D-EF4520292A36 Q28543448-E8936F54-FBFA-4357-92FC-AFD1B9923513 Q28546311-F3C0A201-D39C-4CEC-8430-3D5A0B682366 Q30249514-AE011DF8-5492-46F6-B5ED-B38ADC358300 Q30912685-54F73F43-C190-40B3-9016-5AF320A5CC95 Q33707381-3BC598EE-2E30-4FCF-9815-AAE02FC1EA73 Q33890160-FA5774C9-609C-43C1-B1DD-FE3942A14B97 Q33933490-9569F8E0-7BED-4449-8BA3-814D167BCCA6 Q34354430-65A18746-41E0-4464-B712-C259E5647136 Q34448113-DC34E60E-5220-4190-A880-7B616FC1125C Q34705261-8C894BF4-2432-4482-A9ED-894E87873526 Q35180831-7A6F5AEB-1F40-4B06-8B1E-7196E01B4BE3 Q35898128-687BBC1E-4E1B-41AB-A0F5-98CA11E67EFF Q36022444-1F88E228-1DDF-4B34-AA8D-29ED0D88F4DD Q36074417-74101B9B-361D-4721-86E6-B7E57C97F257 Q36293085-8A467F94-8E56-4775-A9D6-235790ED4F9A Q36417640-4D40EAC4-6B9D-47AD-9B0B-53919C8F86F0 Q36520452-24B1A707-0870-4BEF-8429-C6D8A5C44367 Q36520523-FE29C419-64C2-4189-9ABD-17BE2651CC40 Q36568781-02F850DC-0E08-4ABC-A173-1DFBD9DB1BDD Q36579232-1C557844-D1DA-4A55-8919-6BCA9AED985E Q36653022-D9CC2645-3D4B-4400-B3E2-B11172DAD856 Q36843615-3EF5834E-193D-4CDA-852E-DE7F4EEB953C Q36861608-6398E776-935C-4EBE-8EC6-DC13BED8BA82 Q36907574-1AFCEE63-9C52-4B41-8CF3-1BC3CE56F260 Q36973544-9CB4DADB-1DAB-4940-A9C6-6F391A334EEA Q37023829-0E1BECB9-210B-4AFF-95D0-D281CAB45260 Q37025434-DC3C732D-CB35-4538-81FB-021283882D63 Q37029385-3A212064-D811-4511-8E07-86177F261523 Q37037017-B867B967-8005-45E0-ACF7-7B01F12B5669 Q37254919-61A0B942-EA1A-4B5E-82CE-8FDCD415172B Q37260055-090E4952-90F6-4CBD-B5B2-89A54E3953C9 Q37482721-113DDE1D-B13D-45E5-B771-5AD36ACFFFB5 Q37636975-5AF82FD0-DA78-4FEC-941B-1EBBE4AB8383 Q37689254-3FC76C82-EF09-42D8-AFEF-AFCC90194A93 Q38074079-BC27B2A0-BE86-4309-96D0-3858CD3440C0 Q38162919-CBCF6893-2723-43F9-8815-3A2139804376 Q38194533-245009D1-888D-4D7B-B5E7-3C5951FCCE55 Q38350249-5D0A8E03-A2AF-40B9-970D-82D39F07BAAA

P2860

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

http://www.wikidata.org/entity/Q34679207

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@ast

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@en

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@nl

type

label

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@ast

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@en

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@nl

prefLabel

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@ast

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@en

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@nl

P1433

Q34679207-C396531B-68A9-4F56-96A5-989F62C69E64

P1476

Q34679207-4858EFE9-1631-4BB1-BB2E-58960CC23DD8

P2093

Q34679207-025967C6-45F4-4057-A541-47886B01533D

Q34679207-0EF4E6EC-5B5A-4A42-9E05-CF3F36DDB0D6

Q34679207-179C857A-C226-4AFA-90CE-AC7392572A3F

Q34679207-399432C6-E383-4A29-9EDE-C7BF4E1E69F2

Q34679207-61DCB385-D752-4B54-A944-6AD1B8AE8B01

Q34679207-B6B92ABB-CFD6-4322-91E8-7723AC22030D

Q34679207-C808CA61-A83F-45EC-B01D-D1DB4DD94434

Q34679207-CB0EFFB3-C18C-4BE1-9024-C3574D421CAC

Q34679207-EA8AAFDA-A937-43E7-A860-7298B2C43125

P2860

Q34679207-13352125-56BF-4DF7-89C1-8D7041906A07

Q34679207-1A1B002B-B6CA-4923-BF2F-4C979D169BC8

Q34679207-35D0673D-B166-4E9C-B49F-D019D896164A

Q34679207-43FAD4EE-A648-44A8-90CD-0FF21626260D

Q34679207-4504DC96-426C-4750-B225-96BD95F435FB

Q34679207-50C2E15C-A703-4E8A-8BEC-457898DE0246

Q34679207-550BD6CD-91B8-4828-959A-0BA69AB23DE6

Q34679207-58CFD7BC-6810-4E30-8987-87E58FE2016F

Q34679207-60DB27BE-A4DA-44BC-BF69-33FB8AE16C97

Q34679207-61FB8D4F-191A-46A8-A9B4-2FABA419EC1A

P304

Q34679207-34F89D73-2717-4422-AFAE-BD82B6E5F1CE

P31

Q34679207-A44882B1-E771-4218-910F-3D8CB203A2C4

P356

Q34679207-18846E92-CA57-43CE-B4A0-F0CCCBD7690F

P407

Q34679207-DD7558C9-A431-4BA7-8A9F-C449F6025C78

P433

Q34679207-0D1D9504-9AE9-4B13-A8CB-43D017EDD306

P478

Q34679207-5727C0F1-68AF-4CE9-A605-E6112EA0404A

P50

Q34679207-2D13C6A9-75F6-4405-87D2-E0992BD40898

P577

Q34679207-47C20B7A-2687-417E-9D0A-478A836827DF

P698

Q34679207-A754E9AC-FEB6-4AF5-B62B-1492E54EA3EA

P932

Q34679207-930CBD13-6559-4E17-9383-4D244B39190C

P356

JCO.2010.31.4252

P1433

Journal of Clinical Oncology

P1476

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

@en

P2093

Adam C Reese

http://www.w3.org/2001/XMLSchema#string

Harras B Zaid

http://www.w3.org/2001/XMLSchema#string

Janet E Cowan

http://www.w3.org/2001/XMLSchema#string

Joan F Hilton

http://www.w3.org/2001/XMLSchema#string

Katsuto Shinohara

http://www.w3.org/2001/XMLSchema#string

Kirsten L Greene

http://www.w3.org/2001/XMLSchema#string

Maxwell V Meng

http://www.w3.org/2001/XMLSchema#string

Peter R Carroll

http://www.w3.org/2001/XMLSchema#string

Sima P Porten

http://www.w3.org/2001/XMLSchema#string

P2860

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis

Outcomes of localized prostate cancer following conservative management

Cancer statistics, 2010

Rethinking screening for breast cancer and prostate cancer

Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?

Contemporary risk profile of prostate cancer in the United States.

Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Contemporary trends in low risk prostate cancer: risk assessment and treatment

P304

228-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.31.4252

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Matthew R Cooperberg

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21115873

http://www.w3.org/2001/XMLSchema#string

P932

3058278

http://www.w3.org/2001/XMLSchema#string